Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of CAPRELSA is substantial.
Clinical Added Value
minor
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
Listen
